Search > Amblyopia
24 Participants NeededMy employer runs this trial

Psilocybin for Lazy Eye

(PATCH Trial)

BW
Overseen ByBrian Winston
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Johns Hopkins University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate whether ingestion of a drug called psilocybin can increase the effectiveness of amblyopia therapy in adults with amblyopia. Psilocybin is a naturally-occurring psychoactive compound found in many species of mushrooms. It can be ingested orally and can result in strong but short-term (4-6 hours) effects such as changes in perception, thoughts, and emotions.

Who Is on the Research Team?

FB

Frederick Barrett, MD

Principal Investigator

Johns Hopkins University

Are You a Good Fit for This Trial?

This trial is for adults with amblyopia (lazy eye), including those caused by differences in vision between the two eyes. Participants must be generally healthy and able to safely take psilocybin, as determined by the study team.

Inclusion Criteria

Have given written informed consent
Agree to consume approximately the same amount of caffeine-containing beverage as usual before drug session
I am between 18 and 65 years old.
See 10 more

Exclusion Criteria

I have been diagnosed with schizophrenia or another psychotic disorder.
Current or past severe alcohol or drug use disorder within last five years excluding caffeine and nicotine
My vision loss is caused by an eye condition other than amblyopia.
See 7 more

What Are the Treatments Tested in This Trial?

Interventions

  • Psilocybin

Trial Overview

The study tests if taking different doses of psilocybin (a compound from certain mushrooms) can make standard lazy eye therapy more effective in adults. Participants receive both amblyopia therapy and a single dose of psilocybin.

How Is the Trial Designed?

6

Treatment groups

Experimental Treatment

Group I: 5 mg Psilocybin with Amblyopia TherapyExperimental Treatment2 Interventions
Group II: 25 mg Psilocybin with Amblyopia TherapyExperimental Treatment2 Interventions
Group III: 20 mg Psilocybin with Amblyopia TherapyExperimental Treatment2 Interventions
Group IV: 15 mg Psilocybin with Amblyopia TherapyExperimental Treatment2 Interventions
Group V: 10 mg Psilocybin with Amblyopia TherapyExperimental Treatment2 Interventions
Group VI: 1 mg Psilocybin with Amblyopia TherapyExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Johns Hopkins University

Lead Sponsor

Trials
2,366
Recruited
15,160,000+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.